Pembrolizumab, a programed cell death 1 inhibitor, is a humanized monoclonal antibody that has antitumor activity in advanced NSCLC and unresectable melanoma. 1,2 Vogt-Koyanagi-Harada (VKH) syndrome is a rare condition associated with a systemic immune reaction against melanocytes. Drug-induced VKH syndrome has been reported in patients with melanoma who have received immunotherapy 3,4 ; however, no case of pembrolizumabinduced VKH syndrome has been described in patients with NSCLC. Here we report a case of pembrolizumabinduced VKH syndrome in a patient with NSCLC.